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Abstract: Cytokines play an important part in many pathobiological processes of chronic 
obstructive pulmonary disease (COPD), including the chronic inflammatory process, emphysema, 
and altered innate immune response. Proinflammatory cytokines of potential importance include 
tumor necrosis factor (TNF)-α, interferon-γ, interleukin (IL)-1β, IL-6, IL-17, IL-18, IL-32, and 
thymic stromal lymphopoietin (TSLP), and growth factors such as transforming growth factor-β. 
The current objectives of COPD treatment are to reduce symptoms, and to prevent and reduce 
the number of exacerbations. While current treatments achieve these goals to a certain extent, 
preventing the decline in lung function is not currently achievable. In addition, reversal of cor-
ticosteroid insensitivity and control of the fibrotic process while reducing the emphysematous 
process could also be controlled by specific cytokines. The abnormal pathobiological process 
of COPD may contribute to these fundamental characteristics of COPD, and therefore targeting 
cytokines involved may be a fruitful endeavor. Although there has been much work that has 
implicated various cytokines as potentially playing an important role in COPD, there have been 
very few studies that have examined the effect of specific cytokine blockade in COPD. The two 
largest studies that have been reported in the literature involve the use of blocking antibody to 
TNFα and CXCL8 (IL-8), and neither has provided benefit. Blocking the actions of CXCL8 
through its CXCR2 receptor blockade was not successful either. Studies of antibodies against 
IL-17, IL-18, IL-1β, and TSLP are currently either being undertaken or planned. There is a need 
to carefully phenotype COPD and discover good biomarkers of drug efficacy for each specific 
target. Specific groups of COPD patients should be targeted with specific anticytokine therapy 
if there is evidence of high expression of that cytokine and there are features of the clinical 
expression of COPD that will respond.
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Introduction
Chronic obstructive pulmonary disease (COPD) is defined as a:
… common preventable and treatable disease, characterized by persistent airflow limita-
tion that is usually progressive and associated with an enhanced chronic inflammatory 
response in the airways and the lung to noxious particles or gases. Exacerbations and 
comorbidities contribute to the overall severity in individual patients.1
COPD is currently one of the most important causes of morbidity and mortality 
worldwide, and is predicted to become the third-leading cause of death by 2020. The 
estimated annual costs of COPD in the US are ∼$50 billion, and most of these costs 
are related to exacerbations requiring hospitalization.
International Journal of COPD 2014:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
398
Caramori et al
The etiology of COPD appears to point to interactions 
between environmental factors (particularly cigarette smok-
ing) and genetic factors.2 Chronic cigarette smoking is 
currently the cause of more than 90% of cases of COPD in 
Westernized countries,1,3 but recent studies have described 
a significant prevalence of COPD amongst never-smokers. 
In some countries, such factors as environmental indoor 
pollution from the use of coal or biomass fuel consumption 
may be an important cause.4
The pathological hallmarks of COPD are destruction of the 
lung parenchyma with pulmonary emphysema,  inflammation 
of the small airways with respiratory bronchiolitis, and inflam-
mation of the central airways with chronic bronchitis.5–7 The 
progressive chronic airflow limitation in COPD is likely to 
result from two major pathological processes: remodeling 
and narrowing of small airways, and destruction of the lung 
parenchyma, with the consequent loss of the alveolar attach-
ments of these airways.8 Both small-airway remodeling and 
narrowing and pulmonary emphysema are associated with 
chronic inflammation in the lung periphery.8,9 Pulmonary 
emphysema usually only appears with increasing severity of 
COPD, and can also be present, even severe and diffuse, in 
subjects without airflow obstruction.10 When emphysema is 
moderate or severe, loss of elastic recoil becomes overwhelm-
ingly important, and thus may mask the effects of bronchiolar 
disease on chronic airflow limitation. By contrast, when 
emphysema is mild, the contribution of bronchiolar abnor-
malities to chronic airflow limitation is evident.11
Many patients with COPD have chronic bronchitis 
with increased sputum production. The presence of chronic 
bronchitis may be a predictor of COPD-related death, 
increased risk of pneumonia, and accelerated decline in 
lung function.12,13 The pathophysiological relationships 
between airway mucus secretion and COPD are complex. 
Mucus is the main component of sputum, and its specific 
viscoelastic and rheological properties are due to the pres-
ence of mucins, which are large high-molecular-weight 
oligomeric glycoproteins. Mucins are the main component of 
lower-airway mucus, and several mucins (including MUC2, 
MUC5AC, MUC5B, MUC6, and MUC8) are secreted in the 
lower airways.14–16 Airflow obstruction in COPD is caused 
by small (peripheral) airway lesions, and their intraluminal 
amount of mucus is increased17 and correlates with the degree 
of severity of stable COPD.9
Such comorbidities as cardiovascular disease, meta-
bolic syndrome, osteoporosis, depression, lung cancer, and 
skeletal muscle dysfunction are now recognized to have an 
 important negative impact on quality of life and survival.18 
Other  considerations in the pathophysiology of COPD include 
the development of pulmonary hypertension from hypoxic 
vasoconstriction and the emphysematous process, and the 
occurrence of exacerbations, the frequency of which is usually 
increased with disease severity and triggered mainly by infec-
tions, but also by other such factors as particulate pollution.19
Airway and lung inflammation is a predominant feature 
of COPD.2,8 Although cigarette smokers who do not have 
COPD have a degree of inflammation, those with COPD 
have a far greater degree of inflammation that progresses with 
advancing disease,9 sometimes accompanied by systemic 
inflammation, and inflammation in other nonpulmonary 
organs, such as the heart, blood vessels, and skeletal muscle.18 
Squamous dysplasia is a feature of cigarette smokers that 
may be a precursor to the development of non-small-cell lung 
cancer. Apoptosis remains a potential mechanism underlying 
alveolar destruction, with breakdown of extracellular matrix 
in lung parenchymal tissues. Conversely, there is an increase 
in extracellular matrix in the small airways.7
On the basis of currently available treatments and their 
effects, the objectives of treatment are to reduce symptoms 
and to prevent and reduce the number of exacerbations. 
These goals are achievable, but preventing decline in lung 
function can be more difficult and is probably not achievable 
currently. Bronchodilators form the backbone of symptom-
atic treatment, and the improved long-acting β
2
-agonists and 
anticholinergics, possibly in combination, provide the best 
form of bronchodilator therapy for COPD, with the additional 
effect of reducing the exacerbation rate.1 The addition of 
inhaled corticosteroids to bronchodilator therapy is advocated 
for patients with frequent exacerbations, particularly those 
with more advanced disease. There has been no other addition 
to current treatment options for COPD apart from the recent 
introduction of the phosphodiesterase-4 inhibitor roflumilast, 
which may be useful in reducing exacerbations in patients 
with severe airflow obstruction and chronic bronchitis.1 
Although current developments are focusing on improved 
once-daily combinations of bronchodilators and corticoster-
oids, perhaps the most promising approach to finding agents 
that will stop disease progression or even prevent the decline 
in lung function and reverse the disease process is to block 
aspects of the inflammatory and remodeling processes.20 
Targeting specific cytokines may be important in this.
Overview of inflammation  
in the pathogenesis of COPD
The cellular inflammation in stable COPD is  characterized 
by the presence of increased numbers of  macrophages, 
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 neutrophils, T lymphocytes, dendritic cells and B lympho-
cytes.5–8 Increased numbers of neutrophils and B lymphocytes 
are usually associated with the most severe COPD.5,8 Dur-
ing COPD exacerbations, there is also a recruitment of 
eosinophils, particularly during virus-induced severe COPD 
exacerbations.21 T lymphocytes in COPD are predominantly 
CD8+, but CD4+ cells are also increased. T-helper (Th)-1 and 
T-cytotoxic (Tc)-1 subtypes, characterized by production of 
interferon (IFN)-γ, predominate,5 although Th2 cytokines 
are also increased in stable COPD patients with increased 
interleukin (IL)-4 expression in CD8+ cells (Tc2 cells) from 
bronchoalveolar lavage (BAL).22 In the blood, there are 
increased proportions of IFNγ+ and TNFα+ CD8+ T-cells in 
stable COPD patients correlating with Global initiative for 
chronic Obstructive Lung Disease grades when compared 
with healthy never-smoking controls.23 An increased number 
of Th17 cells is also present in bronchial biopsies of patients 
with stable COPD.24
Many inflammatory cells and mediators are involved in 
the inflammatory process of COPD. It is clear that  cigarette 
smoke itself can directly activate many cells, such as epithelial 
cells or macrophages, to release cytokines and chemokines, 
leading to inflammatory cell recruitment and activation and 
to tissue destruction.2 TNFα, IL-1β, granulocyte- macrophage 
colony-stimulating factor (GM-CSF), and CXCL8 (IL-8) 
are released by airway epithelial cells exposed to cigarette 
smoke,2,25 in addition to transforming growth factor (TGF)-β1, 
which is implicated in the activation of myofibroblasts and 
airway smooth-muscle cells to cause proliferation and 
 fibrosis.26 Alveolar macrophages are also activated by ciga-
rette smoke extract to release a similar profile of cytokines as 
epithelial cells, including TNFα, CXCL8, CCL2 (monocyte 
chemoattractant protein [MCP]-1) in addition to leukotriene 
B
4
 and oxidants (reactive oxygen species).25,26 Alveolar mac-
rophages, like bronchial epithelial cells, can also release a 
number of other chemokines, including CXCL9 (monokine-
induced by IFNγ), CXCL10 (IFN-inducible  protein 10) and 
CXCL11 (IFN-inducible T-cell alpha chemoattractant), 
which are chemotactic for CD8 T cells through the CXCR3 
receptors.25 In addition, there is the synthesis of elastolytic 
enzymes, such as matrix metalloproteinase-2 (MMP-2), 
MMP-9, MMP-12, and  cathepsins.27 Regulation of these 
cytokines is likely to be under the control of nuclear factor 
(NF)-κB, which is activated in macrophages from COPD 
patients.28 An increased number of macrophages in the lungs 
is probably due to increased recruitment of blood monocytes 
to lungs or due to increased local proliferation and survival 
of lung macrophages.25
There are increased numbers of neutrophils in sputum 
and BAL in COPD, and their numbers correlate with disease 
severity.6 Chemotactic signals for neutrophil  recruitment 
include leukotriene B
4
, CXCL1 (previously known as 
growth-related oncogene [GRO]-α), CXCL2 (GROβ), 
CXCL3 (GROγ), CXCL5 (epithelial neutrophil-activating 
peptide 78), and CXCL8, the expression of which is increased 
in COPD, and likely to be derived from alveolar macrophages 
and epithelial cells.25 GM-CSF and granulocyte CSF may 
increase the survival of neutrophils.25
There is now increasing interest in the participation 
of the inflammasome in COPD, which could be the origin 
of some cytokines. The inflammasome’s primary role is 
defending against invading pathogens, including bacteria 
and viruses. The innate immune system is characterized 
by its ability to recognize and respond to an array of infec-
tious agents and endogenous molecules, such as double-
stranded deoxyribonucleic acid and extracellular adenosine 
 triphosphate released during cell and tissue injury. This is 
mediated through the detection of these pathogen-associated 
and danger-associated molecular patterns by receptors termed 
pattern-recognition receptors. These include the Toll-like 
receptors (TLRs), the intracellular retinoic acid-inducible 
gene-like helicases, and the intracellular nucleotide-binding 
oligomerization domain-like receptors (NLRs). NLRs are 
characterized by three domains, including an N-terminal 
interaction domain that mediates protein–protein  interactions 
with downstream signaling intermediates and that can be 
used to categorize the NLRs into five subfamilies: NLRA 
(containing an acidic transactivation domain), NLRB 
 (containing a baculovirus inhibitor of apoptosis protein 
repeat), NLRC (containing a caspase-recruitment domain), 
NLRP (containing a pyrin domain), and NLRX (containing 
an unknown domain). NLRs respond to pathogen-associated 
and danger-associated molecular patterns through the for-
mation of inflammasomes: multimeric cytoplasmic protein 
complexes that act as molecular platforms for the activation 
of inflammatory caspases following stimulation by foreign 
agonists. A typical inflammasome is composed of an NLR, 
an adaptor protein, such as apoptosis-associated speck-like 
protein containing a caspase-recruitment domain (ASC), and 
an effector caspase that activates proinflammatory cytokines, 
in particular IL-1β and IL-18. Three NLR proteins have been 
shown to form inflammasomes: NLRP1, NLRP3 (NALP3, 
also known as cryopyrin or pyrin-containing Apaf 1-like 
protein 1), and NLRC4 (also known as Ipaf). Stimulation of 
the NLRP3 leucine-rich repeat domain by a foreign  agonist 
is postulated to unfold the NLRP3 molecule, enabling 
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 recruitment of the ASC adaptor proteins and procaspase 1. 
Thus, the inflammasome acts as a platform for the autoprote-
olytic cleavage of procaspase 1 to produce active caspase 1, 
which in turn cleaves pro-IL-1β and pro-IL-18 to promote 
their secretion in conjunction with the alarmin high-mobility 
group box 1.29 In COPD, there is evidence of an increase in 
the number of CD8 T-cells expressing TLRs 1, 2, 4, 6, and 
TLR2/1, with only TLR2/1 increased on lung CD4 T-cells 
and TLR2 on CD8 natural killer T-cells.30 There is evidence 
that TLRs are involved in the release of cytokines, such as 
IL-12 and IL-17 from T-cells.
There is a very long list of cytokines and chemokines that 
have been implicated in the many facets of the pathogenesis of 
COPD. Some of these have been supported through genome-
wide association studies on COPD, lung function, and COPD 
complications.31 Proinflammatory cytokines of importance 
include TNFα, IFNγ, IL-1β, IL-6, IL-17, IL-18, IL-32, and 
thymic stromal lymphopoietin (TSLP). Several chemokines 
are also involved, but these have been recently reviewed24 
and so will not be reviewed here, outside of CXCL8, which 
has traditionally been considered as a cytokine. Among the 
growth factors, we will review the role of TGFβ superfamily 
and other profibrotic growth factors with more published data 
on their potential role in the pathogenesis of COPD.
Individual cytokines involved  
in the pathogenesis of COPD
IL-1
Both IL-1α and -β bind to a single IL-1 receptor (named 
IL-1R1), and are proinflammatory cytokines produced 
mainly by monocytes, macrophages, and fibroblasts.32,33 
Mice lacking IL-1R1 have reduced neutrophilic inflamma-
tory response to cell death, but not to a bacterial infection, 
and decreased  tissue damage from inflammation, whereas the 
acute monocyte response to cell death, important for tissue 
repair, is much less reduced,34 suggesting that blocking the 
IL-1 pathway will not affect the host response to microbial 
pathogens. The IL-1 receptor antagonist (IL-1RN or IL-1RA) 
binds to IL-1R and inhibits the binding of both IL-1α and -β, 
neutralizing their activity, and thus acting as an endogenous 
counterregulatory mechanism.35
Cells immunoreactive for IL-1α and -β are increased 
in bronchial biopsies from patients with stable COPD 
 compared to non-COPD controls,36 even though this finding 
for IL-1β was not recently confirmed.29 There are increased 
levels of serum, sputum, and BAL IL-1β37–40 in patients with 
stable COPD. Animal models of COPD provide discordant 
data on the role of the NLRP3 inflammasome in driving 
IL-1β-modulated smoke-induced lung inflammation.38,41,42 
Originally, it was suggested that IL-1β played a role in 
smoke-induced emphysema and airway remodelling,41 but 
more recent data in mice favor a role for inflammasome-
independent induction of IL-1β in driving smoke-induced 
inflammation.38,42 This is in line with a recent unpublished 
clinical trial showing that canakinumab, a monoclonal anti-
body neutralizing IL-1β, was ineffective in the  treatment of 
stable COPD.43 Another IL-1β blocking antibody, MEDI8986, 
is currently undergoing a clinical trial in COPD.44
IL-5
IL-5 is a cytokine produced by the Th2 lymphocytes usually 
associated with asthmatic airway inflammation, but may 
also be involved in the pathogenesis of COPD, particularly 
during exacerbations. Sputum levels of IL-5 protein, BAL 
T-cell IL-5 expression, bronchial mucosal IL-5 messenger 
ribonucleic acid (mRNA) and peripheral lung IL-5 protein 
expression in patients with stable COPD are low/absent and 
not different from control subjects.45–48 Similarly, the number 
of IL-5+ immunoreactive cells is not significantly different 
in the bronchial mucosa (including submucosal glands) of 
patients with chronic bronchitis, with or without COPD, 
when compared with control subjects, and interestingly, other 
cells (mainly plasma cells) outside of T lymphocytes are the 
major sites of IL-5 production.49–51 Sputum levels of IL-5 
in patients with stable COPD correlate with the degree of 
eosinophilia and response to glucocorticoids of these patients, 
suggesting that these subjects have an overlap syndrome 
asthma/COPD.52,53 In addition, soluble IL-5Rα is increased 
during virus-induced COPD exacerbations,54 but in patients 
with mild/moderate COPD during an exacerbation of the 
disease, IL-4 and IL-5 expression was not changed compared 
to stable disease.50,55
GM-CSF
GM-CSF is released in the COPD lung mainly from infiltrat-
ing cells.56 Proinflammatory cytokines, such as TNFα, IL-17, 
and bacterial lipopolysaccharide can induce in vitro the 
release of GM-CSF from cells. In vitro exposure to  cigarette 
smoke extract decreases the release of GM-CSF from bron-
chial epithelial cell lines,57 and in line with this effect, a single 
exposure to cigarette smoke decreased lung GM-CSF mRNA 
in animals,58 but in animal models, repeated cigarette smoke 
exposure increased lung GM-CSF expression.59,60 In mouse 
models of cigarette smoke and lipopolysaccharide exposure, 
treatment with a neutralizing anti-GM-CSF monoclonal 
antibody reduced the number of BAL macrophages and 
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neutrophils and the lung expression of many inflammatory 
mediators.61–64 In vitro stimulation of CD8+ T-cells isolated 
from the lungs of patients with stable COPD using anti-
CD3-ε antibodies activating the T-cell receptor induced the 
secretion of GM-CSF.65 There are no published studies com-
paring if these cells isolated from the lungs of age-matched 
control smokers with normal lung function released different 
amounts of GM-CSF compared with those isolated from the 
lungs of patients with COPD. Sputum levels of GM-CSF, 
but not peripheral lung GM-CSF expression, were increased 
in patients with stable COPD compared to control subjects 
in some studies56,66 and decreased in others.67 There are no 
published studies using GM-CSF blockers in patients with 
COPD. MOR103 is a fully human monoclonal antibody that 
selectively neutralizes human GM-CSF, and is being devel-
oped in the area of inflammatory diseases, ie, rheumatoid 
arthritis (http://www.morphosys.com/node/2563).
IL-6
IL-6 may play an important role in the progression of COPD 
severity.68 IL-6 may also contribute to the pathogenesis of the 
autoimmune response observed in the lungs of the patients 
with more severe stable COPD.69 IL-6 is a potent inductor 
of C-reactive protein (CRP) production in the liver, and 
increased IL-6 plasma levels are associated with increased 
CRP levels in patients with stable COPD.70,71 Plasma levels 
of IL-6 are increased in patients with stable COPD compared 
to controls,72 are persistent in their duration, and may con-
tribute to the increased risk of depression associated with 
COPD and also to its mortality.73–77 However, other studies 
suggest that increased plasma levels of IL-6 are limited to 
patients with stable COPD and concomitant cardiovascu-
lar  comorbidities.78 IL-6 levels are also increased in the 
sputum of patients with stable COPD compared to control 
subjects.79,80 Several anti-IL6 blocking antibodies have been 
developed and have been used in clinical trials of rheumatoid 
arthritis and several cancers with some efficacy,81 but there 
are no data on patients with COPD. Interestingly, COPD 
patients who walked the most had the lowest plasma CRP 
and IL-6, suggesting that an intervention to promote walking 
may reduce systemic inflammation in COPD.82
Thymic stromal lymphopoietin (TSLP)
TSLP is a cytokine of the IL-7 family, is produced mainly 
by stromal cells, including mast cells,83–86 and is involved in 
the activation, expansion, and survival of T lymphocytes and 
dendritic cells. TSLP expression in the airway epithelium is 
inducible through a NF-κB-dependent pathway.87,88 Its action 
is mediated by a heterodimeric receptor composed of IL-7Rα 
and TSLP receptor (TSLPR). Some functions of TSLP and its 
receptor overlap that of IL-7 and its receptor, despite signal-
ing predominantly through signal transducer and activator of 
transcription (STAT)-5 at variance with IL-7Rα, and thus this 
represents an alternative pathway to the IL-7/IL-7Rα axis. 
In human airway smooth-muscle cells, TSLPR signaling is 
mainly mediated by STAT3.89
In vitro TSLP and TSLP-R expression in human airway 
smooth-muscle cells is increased after chronic exposure to 
cigarette smoke extract,90 and TSLP is a mediator of cross 
talk between airway smooth-muscle and mast cells.91 TSLP 
and TSLP-R-blocking antibodies neutralize the increased 
contraction of airway smooth-muscle cells induced by ciga-
rette smoke extract,90 suggesting a role for this pathway in 
bronchoconstriction. TSLP has also been implicated in the 
induction of glucocorticoid resistance in Th cells during 
airway inflammation by controlling the phosphorylation 
of STAT5.92 In addition, TSLP may amplify alternatively 
activated airway macrophage polarization and chemokine 
production.93 An increased number of cells expressing TSLP 
mRNA has been reported in the bronchi of stable COPD 
patients and control smokers with normal lung function,94 
and increased TSLP immunostaining has been shown in the 
smooth muscle of patients with stable COPD compared to 
nonsmoking subjects.95 Blocking antibodies have been devel-
oped (http://www.freepatentsonline.com/8232372.html),96 
but there have been no studies on COPD so far.
CXCL8
CXCL8 levels are markedly elevated in the sputum of patients 
with stable COPD, and are correlated with disease severity.97,98 
Blocking antibodies to CXCL8 and related chemokines inhib-
its certain types of neutrophilic  inflammation in experimental 
animals.99 The neutralization of CXCL8 with a blocking 
antibody significantly reduces the neutrophil chemotactic 
activity of sputum from patients with stable COPD;100,101 
however, this reduction is only partial, indicating that other 
neutrophil chemotactic factors, such as leukotriene B
4
 and 
the activated complement factor C5a, are also involved.99 
However, CXCL8 plays a major role in neutrophil chemotaxis 
caused by alveolar macrophage-derived conditioned media, 
and this is most effectively inhibited by dual antagonism of 
CXCR1 and CXCR2 receptors.102
The mean sputum levels of CXCL8 are significantly 
higher in α
1
-antitrypsin-deficient patients than in patients 
with COPD with normal levels of α
1
-antitrypsin,103 and 
enhanced CXCL8 expression is associated with increased 
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neutrophil chemotactic activity of sputum from patients. 
In addition, there is an increase in BAL levels of CXCL8 in 
current smokers with pulmonary emphysema and in stable 
COPD.104,105 A slight, albeit significant, increase of CXCL8 
protein epithelial expression is present in the bronchial 
mucosa of severe stable COPD patients compared to control 
healthy smokers.106 In contrast, no significant differences 
are observed in the submucosa of stable COPD and control 
subjects at both mRNA and protein level,106 suggesting a 
minor role of this chemokine in the bronchial mucosa of 
stable COPD patients.
The expression of CXCL8 mRNA and protein is increased 
1.5-fold in the bronchiolar epithelium of patients with COPD 
compared to control subjects.107,108 There is also increased 
expression of CXCR2 mRNA, a CXCL8 receptor, in the 
bronchiolar epithelium of COPD patients compared to con-
trol subjects, suggesting that this axis may be relevant in the 
recruitment of neutrophils to the small airways.109 A mono-
clonal antibody against CXCL8 improved dyspnea in patients 
with COPD, but had no effect on lung function, health sta-
tus, or 6-minute walking distance.110 A CXCR2 antagonist 
(navarixin, formerly CH527123) reduced sputum neutrophils 
in patients with stable COPD, but has not shown any clinical 
benefit.111 Another CXCR2 antagonist (AZD5069) reduced 
blood neutrophils in patients with stable COPD without any 
clinical benefit.112 The efficacy of the oral CXCR2 antago-
nist danirixin (formerly GSK1325756B) is currently being 
investigated in a 1-year clinical trial of patients with mild-
to-moderate COPD (http://www.gsk-clinicalstudyregister.
com/study/200163#ps).
IL-17
IL-17, also known as IL-17A, is produced predominantly 
by CD4 and CD8 T-cells,113 known respectively as Th17 and 
Tc17 cells, and can be induced in vitro by different combi-
nations of TGF-β, IL-1 β, IL-2, IL-6, IL-15, IL-18, IL-21, 
and IL-23.114 Human regulatory T-cells can differentiate into 
IL-17-producing cells when stimulated by monocytes in the 
presence of IL-2/IL-15.115 Th17 cells in addition to IL-17A 
also release IL-17F, IL-21, IL-22, GM-CSF, and CCL20, and 
are critical for the clearance of extracellular pathogens, but 
under certain conditions are associated with the pathogenesis 
of several autoimmune and inflammatory diseases.116 IL-17A 
induces the release of CXCL1, CXCL8 and GM-CSF from 
airway epithelial cells and smooth-muscle cells, and thereby 
may orchestrate neutrophilic inflammation.117–119 IL-17A 
can induce IL-6 expression in bronchial epithelial cells and 
fibroblasts,117 and IL-17A, in conjunction with IL-6, is able to 
induce MUC5AC and MUC5B production in primary human 
tracheobronchial epithelial cells.120 IL-17A is also involved 
in human airway smooth-muscle contraction.121
Serum IL-17A levels are increased in patients with 
stable COPD compared to healthy smokers and nonsmok-
ers, increase with COPD stage, and are inversely correlated 
with predicted forced expiratory volume in 1 second (FEV
1
) 
percentage.122 IL-17+ neutrophils are present in induced spu-
tum from patients with stable COPD, but it remains unclear 
whether the sputum levels of IL-17A are increased in patients 
with stable COPD.122,123 There is a significant increase in the 
number of IL-17A+ immunoreactive cells in the bronchial 
submucosa of mild/moderate and severe COPD patients 
compared to control nonsmokers,24,124 and in the peripheral 
lungs of stable COPD patients compared to smokers with 
normal lung function and nonsmoking subjects.122,125
Anti-IL-17 antibody in cigarette smoke-exposed mice 
reduced IL-17 levels in lung homogenates, and reduced 
neutrophil response in BAL and the degree of small-airway 
inflammation.126 Th17 cells have been shown to mediate glu-
cocorticoid-resistant airway inflammation and airway hyper-
responsiveness in mice.127 In IL-17–/– mice exposed to cigarette 
smoke, neutrophil inflammation and the number of apoptotic 
type 2 alveolar cells were decreased.128 IL-17RA is required for 
CCL12 expression, macrophage recruitment, and pulmonary 
emphysema secondary to cigarette smoke,129 and also for the 
development of elastase-induced pulmonary emphysema,130 
but not oxidant-induced emphysema.131 IL-17 neutralizing, as 
well as anti-human IL-17R (such as brodalumab) antibodies 
are currently available for clinical studies in COPD, having 
recently been reported in a study of patients with asthma.132
IL-18
IL-18 (previously termed IFNγ-inducing factor) is produced 
by alveolar macrophages and the airway epithelium. IL-18 
binds to its receptor (IL-18R) subunit-α (IL-18R1),133 but 
the signaling activity requires also the presence of the 
β-subunit (also termed IL-18R accessory protein or acces-
sory  protein-like).134,135 In the presence of IL-12, IL-18 has 
an important role in Th1/Tc1 polarization. In fact, IL-12 
increases IL-18R expression by Th1 cells, promoting Th1-
cell polarization and proliferation, secretion of IFNγ, and 
macrophage and neutrophil accumulation.135,136 However, 
in the absence of IL-12, IL-18 induces the release of Th2 
and Th17 cytokines (eg, IL-4, IL-5, IL-9, and IL-13). IL-18 
can also act as a cofactor for Th2-cell development and 
immunoglobulin (Ig)-E production, and also plays an impor-
tant role in the differentiation of Th17 cells.135,136 Within the 
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NRLP3 inflammasome complex, autocatalytic cleavage of 
procaspase 1 to active caspase 1 enables removal of IL-1β 
and IL-18 prosequences, resulting in biologically active 
forms of IL-18.137,138
IL-18 may represent a novel master cytokine regulator 
that can drive all of the key pathologies found in stable 
COPD.139 IL-18R1 plays a critical role in the pathogenesis of 
cigarette smoke-induced pulmonary emphysema and inflam-
mation.140–142 IL-18-mediated alveolar endothelial cell death 
may also contribute to vascular destruction and disappearance 
in chronic secondhand smoke exposure-induced pulmonary 
emphysema.143,144 Furthermore, transgenic mice overex-
pressing IL-18 in the mature lung show lung inflammation 
with increased numbers of CD4+, CD8+, CD19+, and natural 
killer 1.1+ cells, pulmonary emphysema, mucus metaplasia, 
airway fibrosis, vascular remodeling, and right ventricle 
cardiac hypertrophy.145 There are increased levels of plasma 
and sputum IL-18146–149 in patients with stable COPD com-
pared to control smokers and nonsmokers. There is also an 
increased percentage of IL-18Rα-expressing T lymphocytes 
and CD8+ T-cells in stable COPD patients compared with 
control subjects.149 IL-18R protein expression is higher on 
alveolar macrophages in peripheral lungs from stable very 
severe COPD patients compared to control subjects.150
The safety of MEDI2338, a monoclonal IgG
1
 anti-
body blocking human IL-18 (http://www.ncats.nih.gov/
files/MEDI2338.pdf), in stable COPD patients has been 
evaluated,151 but apparently its development has been 
discontinued.
IL-22
IL-22 is expressed predominantly in Th1 and Th17 cells, 
particularly in the presence of IL-23,152 which is also 
increased in the epithelium and submucosa of stable COPD 
patients.24 In animal models, IL-22 is a crucial effector 
molecule in host defense against Gram-negative bacterial 
pneumonia.153 Serum and sputum IL-22 are significantly 
increased in the sputum of stable COPD patients, particu-
larly in advanced grades, and of control smokers with nor-
mal lung function compared with nonsmoking subjects.122 In 
the bronchial mucosa, immunostaining for IL-22 is localized 
to endothelial cells, inflammatory cells, and fibroblasts, and 
the number of IL-22+ immunoreactive cells was increased 
significantly in the bronchial epithelium of severe and mild/
moderate stable COPD compared to control nonsmokers, 
but did not differ in comparison with control smokers with 
normal lung  function.24 The number of IL-22+ cells in the 
bronchial submucosa was significantly higher in severe and 
mild/moderate COPD compared to control nonsmokers, but 
did not differ in comparison with control smokers with nor-
mal lung function.24 The proportions of blood IL-22+ cells in 
the CD4+ memory (CD45RA–CD45RO+) T-cell population 
were significantly increased in COPD active smokers, when 
compared with ex-smokers.23 Human bronchial epithelial 
cells also express IL-22R and IL-17, and IL-22 increases 
the expression of antimicrobial proteins, such as lipocalin-2, 
in airway epithelial cells,154 even though in animal models 
neither administration of IL-22 nor of IL-22 blocking 
 antibodies has any effect on lung neutrophilia.155
IL-23
In animal models, chronic cigarette smoke exposure increases 
the expression of IL-23 in the lungs.156,157 In bronchial 
mucosa, immunostaining for IL-23 is localized in endothelial 
cells, inflammatory cells, and fibroblasts, and the number 
of IL-23+ immunoreactive cells is increased in the bronchial 
epithelium of stable COPD patients compared with control 
groups,24 but in the human lung there is no significant dif-
ference in the expression of IL-23R between COPD and 
control groups.158 In contrast, the number of IL-23+ cells in 
the bronchial submucosa was significantly higher in severe 
stable COPD patients compared to control nonsmokers, but 
did not differ in comparison with control smokers or mild/
moderate stable COPD.24 These findings are in line with a 
previous demonstration of increased expression of IFNγ and 
of STAT4, its downstream transcription factor, in bronchial 
biopsies from patients with stable COPD.159 IL-23 induces 
the proliferation of memory T-cells and the secretion of IFNγ, 
and in animal models cigarette smoking increases the lung 
expression of IL-23.156,157 IL-17A production by Th17 cells is 
induced by IL-23.160,161 In vitro, the COPD-associated patho-
genic bacteria Haemophilus and Moraxella spp. provoke a 
3-5-fold higher production of IL-23 from human monocyte-
derived dendritic cells compared to lung commensal bacte-
ria,162 suggesting a potential link between chronic bacterial 
colonization of the lower airways, often present in COPD,163 
and the development of lung cancer in COPD patients, eg, 
by amplification/perpetuation of airway inflammation, which 
has been linked with multiple molecular mechanisms in the 
promotion of lung cancer.164 Blocking anti-IL-23 antibodies 
are effective against neutrophilic inflammation in several 
diseases and in animal models.165
IL-33
IL-33 is another member of the IL-1 family, and is local-
ized to the chromatin in the cell nucleus.166 The cytokines of 
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the IL-1 family – IL-1α/β, IL-1Ra, and IL-18 – have been 
matched to their respective receptor complexes, but the ligand 
for the most prominent orphan IL-1R, ST2,167 is IL-33.166 
Three distinct types of ST2 (also termed IL-33R, IL-1RL1, 
T1, Fit-1, and DER4) exist; a soluble secreted form (ST2), 
a transmembrane receptor form (ST2L), and a variant form 
(ST2V). There is constitutive expression of IL-33 mRNA in 
bronchial smooth-muscle cells, bronchial epithelial cells, and 
high endothelial venule endothelial cells.167,168 The expres-
sion of IL-33 may also be enhanced through activation of 
the inflammasome.169
IL-33R (or ST2) is selectively expressed on Th2 cells (where 
it stimulates the production of IL-4) and on mast cells.167,170 
Soluble ST2 receptor is considered anti- inflammatory in 
animal models,171 and its plasma level is increased in mild/ 
moderate stable COPD compared to control smokers with 
normal lung function.172 In animal models after exposure to 
tobacco smoking, the lung expression of IL-33 and ST2 is 
markedly enhanced and associated with neutrophil and mac-
rophage infiltration and expression of inflammatory cytokines 
(IL-1β, TNFα, IL-17), chemokines (CCL2), and MUC5AC in 
the lower airways. These changes are all significantly prevented 
by treatment with neutralizing anti-IL-33 antibody.173
TNFα
TNFα is an important chemotactic protein for neutrophils; in 
fact, the inhalation of TNFα induces sputum neutrophilia and 
airway hyperresponsiveness in normal subjects.174 In vitro, 
TNFα also induces CCL13 (monocyte chemoattractant 
protein 4) expression, a chemokine with potent chemotactic 
activities for eosinophils, monocytes, T lymphocytes, and 
basophils. TNFα may also activate structural (such as epi-
thelial and smooth-muscle cells) and inflammatory cells of 
the airways to release inflammatory mediators (such as oxi-
dants).175,176 TNFα stimulates the secretion of MUC5AC from 
bronchial epithelial cells,177 upregulates adhesion–molecule 
expression on inflammatory, epithelial, and endothelial cells, 
facilitates the migration of inflammatory cells into the lower 
airways, and activates profibrotic mechanisms involved in 
airway remodeling.175,176
TNFα levels are increased in the blood and sputum of 
COPD patients.72,97 They also have significantly higher levels 
of soluble TNFR1 in sputum and TNFR2 in blood. In addi-
tion, sputum sTNF receptors, but not blood sTNF receptors, 
are inversely related to FEV
1
 in patients with COPD.178 COPD 
patients also show an increased TNFA gene expression in 
their skeletal muscles.179 The severe weight loss present in 
some patients with advanced COPD might also be due to 
skeletal muscle-cell apoptosis (muscle cachexia), as a result 
of increased levels of circulating TNFα.175,180
Glucocorticoids, low-dose theophylline, phosphodiesterase-4 
inhibitors, and p38 mitogen-activated protein-kinase inhibi-
tors potently inhibit TNFα production in vitro and/or in 
vivo.181 Selective TNFα inhibitors in clinical development 
include nonhuman or chimeric antibodies (infliximab, 
afelimomab, and CytoTab), humanized antibodies (adali-
mumab and certolizumab pegol [CDP870]), human TNFR 
(onercept), or TNFR fusion protein (etanercept). TNFα-
converting enzyme (ADAM17) is an MMP-related enzyme 
that is required for the release of soluble TNFα, and might be 
another attractive target. Small-molecule TNFα-converting 
enzyme inhibitors, some of which are also MMP inhibitors, 
are in development as oral TNFα inhibitors.175,182
Three studies of infliximab in patients with mild-to-
severe COPD have reported no beneficial effects on various 
clinical parameters, including exacerbations, dyspnea, and 
FEV
1
.183–185 However, in a study of 157 patients with COPD, 
infliximab increased the incidence of pneumonia and malig-
nancy, and more patients receiving infliximab had to discon-
tinue therapy due to adverse events.183 Systemic blockade 
of TNFα can lead to increased risk of infection, recurrence 
of tuberculosis, and reactivation of hepatitis B, as well as 
worsening of congestive heart failure. It has been proposed 
that anti-TNFα therapy may be more beneficial for COPD 
exacerbations than as maintenance therapy, but the TNFα 
blocker etanercept was found to be no more effective than 
prednisone in the treatment of COPD exacerbations.186
TGFβ superfamily and other  
profibrotic growth factors
The TGFβ superfamily consists of secreted growth factors 
involved in the regulation of different cellular processes, 
such as cell growth, development, differentiation, prolifera-
tion, motility, adhesion, and apoptosis.187 Increased levels of 
TGFβ1 have been reported in such lung diseases as COPD, 
asthma, and pulmonary fibrosis.26 TGFβ1 is highly expressed 
in the epithelium and macrophages of small airways in 
patients with COPD, but it is still not known whether this is an 
expression of COPD or the effect of cigarette smoking.188–190 
The bone morphogenic protein and activin membrane-bound 
inhibitor (BAMBI) is a membrane-spanning glycoprotein that 
acts as a negative regulator of TGFβ signaling.191 BAMBI 
is induced by members of the TGF family – β-catenin, 
SMAD3, and SMAD4191 – and acts as a pseudoreceptor.192 
In the peripheral lungs of patients with stable COPD com-
pared with control subjects and in vitro there is a marked 
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upregulation of BAMBI expression (alveolar macrophages 
and alveolar epithelial cells) after infection ex vivo of the 
lung tissue with nontypable Haemophilus influenzae that 
is present in the peripheral lung tissue in around a third of 
patients with stable COPD, but absent in the controls.193 
Connective tissue growth factor is a cysteine-rich peptide 
involved in cell proliferation, migration, and extracellular 
matrix production.194 Conflicting results have been reported 
in peripheral lung tissue from patients with stable COPD 
showing downregulation195 or upregulation196 of mRNA for 
connective tissue growth factor compared with control smok-
ers with normal lung function.
There is increased cytoplasmic expression of fibroblast 
growth factor (FGF)-2 in bronchiolar epithelium and its 
nuclear localization in bronchiolar smooth-muscle cells 
in COPD patients compared with controls. In addition, 
increased FGFR-1 expression in bronchiolar smooth-muscle 
cells and increased FGF-1 and FGFR-1 are seen in the bron-
chiolar epithelium from COPD patients.197 In COPD patients, 
an increase in FGF-2 expression is also observed in vascular 
smooth-muscle cells and the endothelium of small pulmonary 
vessels. In contrast, vascular smooth-muscle cells of large 
pulmonary vessels show increased staining for FGF-1 and 
FGFR-1 compared to controls.198
Cytokines in COPD exacerbations
IL-1β, IL-6, CXCL8, IL-10, and TNFα levels are increased 
in sputum supernatants during COPD exacerbations.53,199–204 
Elevated levels of IL-1β in exhaled breath condensate and 
sputum during COPD exacerbations, particularly when associ-
ated with bacterial infections, have been reported.205 Bacterial 
exacerbation has also been associated with higher levels of 
sputum CXCL8 and TNFα, leading to enhanced neutrophil 
recruitment and activation.186,204 Increased sputum CD8+ T 
lymphocytes have been reported during COPD exacerbations, 
with a relative reduction in the ratio of IFNγ/IL-4-expressing 
CD8+ T lymphocytes.204 Therefore, a switch toward a Tc2-like 
immunophenotype during COPD exacerbations could trigger 
recruitment of eosinophils, and might be activated by the 
immune response to some microbial pathogens. However BAL 
CD4 T-cells from patients with COPD exacerbations exhibited 
a Th1 (IFNγ release) and Th2 (IL-4 release) cell–cytokine 
phenotype during acute infection with rhinovirus.206
However soluble, IL-5RA is increased during virus-
induced COPD exacerbations,54 and in animal models 
of COPD after exposure to rhinovirus, there is increased 
lung expression of IL-5.207 In addition, patients with mild/ 
moderate COPD during an exacerbation of the disease show 
an increased number of TNFα mRNA-producing cells in 
their bronchial mucosa in comparison with stable COPD 
patients,50,208 but mRNAs for IL-4 and IL-5 were not changed 
during COPD exacerbations compared to stable disease.50,55 
Severe exacerbations of COPD are associated with increased 
neutrophilia and upregulation of epithelial mRNA for CXCL5 
(epithelial neutrophil-activating peptide 78), CXCL8 (IL-8), 
CXCR1, and CXCR-2 in comparison with stable disease.209 
Systemic inflammation is now increasingly recognized as a 
feature of COPD, and increased serum levels of IL-6 during 
COPD exacerbations have been described.210
Bacterial and virus infection can synergistically interact 
to increase the severity of inflammatory response. Indeed, it 
has been shown that rhinovirus and H. influenzae coinfection 
at COPD exacerbations is associated with increased levels 
of serum IL-6 compared with those exacerbations without 
both pathogens.211 Similarly, levels of endothelin 1, a potent 
vasoconstrictor and bronchoconstrictor peptide with impor-
tant proinflammatory activities in the airways, tend to be 
higher during COPD exacerbation associated with viral 
or chlamydial infection, both in sputum and in plasma.212 
Virus-induced COPD exacerbations are also associated 
with increased plasma levels of IL-10, IL-12, and IL-15,213 
whereas all COPD exacerbations (with or without respira-
tory virus isolation) are characterized by increased plasma 
levels of IL-2, IL-13, and vascular endothelial growth 
factor.213
Plasma levels of IL-21, a cytokine important for B-cell 
development and antibody synthesis,214 are decreased during 
COPD exacerbations compared with stable COPD patients, 
but without statistically significant association between IL-21 
levels and antiviral capsid protein (VP1) of rhinovirus IgG
1
 
antibody concentrations that have shown cross-neutralizing 
activity across different rhinovirus strains.215,216 This deficient 
synthesis of IL-21 might be linked to the susceptibility to 
COPD exacerbations via other mechanisms, eg, IL-21 is also 
critical for CD8 T-cell memory.217
Plasma levels of IL-19 and IL-22 have been shown to be 
decreased during COPD exacerbations.218 IL-19, a proinflam-
matory cytokine, belongs to the IL-10 family, and is expressed 
in epithelial cells, endothelial cells, and  macrophages.219 
Plasma adiponectin concentrations increase during COPD 
exacerbations and return to baseline several days to weeks 
later; the clinical relevance of this is unknown.220
Although many cytokines are potentially involved both at 
the lung level and in terms of systemic inflammation, there 
has only been one study of anticytokine therapy with the 
TNFα blocker etanercept for COPD exacerbations.186
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Inhibiting cytokines  
in COPD: current knowledge  
and future strategies
There is clear evidence for a heightened inflammatory 
response in COPD associated with enhanced expression of a 
number of key cytokines. Although many of these have been 
proposed to play a role in COPD pathophysiology, there have 
been very few trials of agents that block cyto kines, usually 
with blocking antibody approaches. And yet inhibiting cytok-
ines looks like a most promising way of inhibiting the inflam-
matory process that is likely to underpin the progressive nature 
of this disease. So far, clinical experience has been mainly 
limited to the use of anti-TNFα and anti-CXCL8 (IL-8), where 
the effects observed have not been encouraging. The lack of 
effect of an anti-TNFα approach in COPD is in stark contrast 
to the positive beneficial effect of this approach in rheumatoid 
arthritis. This particular experience would beg the question as 
to whether blocking of the other cytokines listed earlier would 
be of ultimate benefit in the treatment of COPD.
Just because the levels of a cytokine or chemokine are 
elevated in COPD does not mean that suppressing its actions 
will necessarily be effective as an anti-inflammatory therapy. 
For example, although the levels of TNFα and CXCL8 are 
both elevated in COPD, and anticytokine approaches proved 
effective in animal models of disease, inhibiting these media-
tors has not been effective in clinical trials of COPD patients. 
Indeed, despite TNFα levels being increased in COPD patient 
sputum and serum and it being known as a major driver of the 
inflammatory response, 6 months’ treatment with infliximab 
showed no clinical benefit, with increased risk of lung cancer 
and pneumonia being observed.185 CXCL8 is chemotactic 
for neutrophils and monocytes, and its levels are increased 
in COPD; however, treatment with an anti-CXCL8 antibody 
was ineffective in COPD, and despite early optimism, more 
than one CXCR2 antagonist has not proved effective in 
large clinical trials either.110,111 Furthermore, canakinumab, 
an anti-IL-1β-specific antibody, has no clinical efficacy in 
COPD either. As listed earlier, other drugs in development 
include antibodies directed against IL-5 (mepolizumab), IL-6 
(eg, tocilizumab), IL-17 (eg, ixekizumab, brodalumab, and 
ustekinumab), IL-18, IL-22, IL-23, IL-33, TSLP, and GM-
CSF. Studies in mouse models may predict the clinical success 
of inhibiting these cytokines selectively, but it is only going 
to be possible to determine whether this approach will work 
by trying these approaches in COPD itself. Compared with 
chemokines, the functional redundancy between different 
cytokines in the pathogenesis of COPD is much less clear, but 
need for targeting groups of cytokines cannot be excluded.
One potential area that may improve success of anticy-
tokine therapies is in the careful selection of patients with 
COPD for these clinical trial studies of specific antimonoclonal 
antibodies. COPD is a mixture of various diseases with distinct 
phenotypes independent of genetic background.221 The clinical 
manifestations of COPD are highly variable between patients, 
and the level of chronic airflow obstruction is not enough to 
encompass the diversity of presentation of COPD.222 Other 
clinical aspects of COPD that contribute to this diversity 
include the degree of pulmonary emphysema and chronic 
bronchitis and the frequency of exacerbations. While defining 
clinical phenotypes of COPD to link with disease outcomes 
is an important outcome of this exercise for both the clinician 
and patient, it is as important to link clinical phenotype to the 
pathophysiological mechanisms that have been delineated so 
far for COPD. Therefore, the identification of the inflammatory 
biomarkers CRP, IL-6, CXCL8, fibrinogen, and TNFα linked 
to mortality indicates the potential importance of these cytok-
ines as targets for COPD treatment. In addition, the COPD 
patient with evidence of eosinophilic biomarkers either in 
blood or sputum may respond to eosinophil-targeted cytokines, 
such as anti-IL-5 antibody, as has been demonstrated in asthma 
patients with evidence of eosinophilic inflammation. At the end 
of the day, it should be possible to define specifically the type 
of inflammation in a particular COPD patient by the expression 
of key cytokines or chemokines. In addition, it makes sense 
to target patients with specific anticytokine therapy if there is 
high expression of that cytokine, and thus direct and indirect 
biomarkers of abnormal cytokine expression will be needed.
The effects of anti-IL-5 and anti-IL-13 antibodies in 
severe asthma223,224 clearly demonstrate the need for both care-
ful patient phenotyping and the need for good biomarkers of 
patient phenotypes and of drug efficacy, so that patients can be 
taken off a treatment if it is ineffective to reduce the risk of any 
possible side effects and to enable a change in drug treatment 
in an adaptive design clinical study or in real life.
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